Read on Twitter
The past 8 years has seen a lot of targeted therapies for ER+ breast cancer.
#MBCImpactNJ @komennewjersey
#MBCImpactNJ @komennewjersey
Immunotherapy is being combined with CDK4/6 with some success in the lab. Not yet in clinical trials. #MBCImpactNJ @komennewjersey
The combo extended PFS by 7.6 months. Now in Phase 3 trial called DESTINY 04. #MBCImpactNJ @komennewjersey
Trastuzumab Deruxtecan now used for HER2-positive drub - an antibody drug conjugate being studied bc research showed the combo also killed HER2 negative cells. #MBCImpactNJ @komennewjersey
Clinical trial study so far showed a 48% clinical benefit of drug for patients who had 5 prior treatments. Nausea, rashes are a side effect. Now in Phase 3 trial. #MBCImpactNJ @komennewjersey
Sacituzumab Govitecan (Trodelvy) is one antibody drug conjugates being studied. Targets TROP2 antibody. More active in treatment of triple negative but looking to expand use. #MBCImpactNJ @komennewjersey
Antibody-drug conjugates new frontier of research. Antibody is linked to a chemotherapy drug. Delivers drug directly to tumor so chemo can work only on cancer. #MBCImpactNJ @komennewjersey
Looking at developing oral drugs. Elastresant (sp?) Emerald study showing promise for both men and women with breast cancer. #MBCImpactNJ @komennewjersey
Now looking at targeting ESR1 mutation with ER+ degradation inhibitors such as Fulvestrant. #MBCImpactNJ @komennewjersey
Ibrance seems to reverse the ESR1 mutation. #MBCImpactNJ @komennewjersey
Research using liquid biopsy/blood draws for CTC are looking at these mutations. Finding this mutation more common after 6 months of hormone therapy.
#MBCImpactNJ @komennewjersey
#MBCImpactNJ @komennewjersey
Mutations in estrogen receptors can lead to resistant. ESR1 mutations are common. 30-50% who progress have that mutation. #MBCImpactNJ @komennewjersey
AKT inhibitors also being looked at. Capivasertib + Fulvestrant. Seeing progression free survival and overall survival. #MBCImpactNJ @komennewjersey
GDC-0077 also being studied as a PIC3A mutation. #MBCImpactNJ @komennewjersey
Now giving anti-histamines to reduce rash. #MBCImpactNJ @komennewjersey
Common Alpselsip side effects are rash, diarrhea and hyperglycemiaissues, ranging from 10% to 3%. #MBCImpactNJ @komennewjersey
PI3KCA inhibitor Alpelisip and Fulvestrant slowed cancer growth for an average of 9.1 to 11 months if the cancer has that mutation. #MBCImpactNJ @komennewjersey
40% of ER+ cancers have a PI3K mutation. #MBCImpactNJ @komennewjersey
CDK4/6 drugs do improve overall survival. #MBCImpactNJ @komennewjersey
Now looking at novel combinations for Verzenio (Abemaciclib). #MBCImpactNJ @komennewjersey
CDK4/6 inhibitors doubled progression-free survival for ER+. Dr. Wong @MSK #MBCImpactNJ @komennewjersey
Cyclin D1, common to ER+ breast cancer, activates CDK4/6. Inhibiting CDk4/6 can slow cancer cell growth. #MBCImpactNJ @komennewjersey
About 30% ER+ are drug resistant. Almost all eventually become resistant.
#MBCImpactNJ @komennewjersey
#MBCImpactNJ @komennewjersey
Number of ways to target estrogen receptor to stop cell growth. #MBCImpactNJ @komennewjersey
